ProQR Therapeutics is a biotech company developing RNA-based therapies for rare genetic diseases, with two lead drugs in late-stage trials targeting inherited blindness conditions.
The company has no product sales and relies on collaboration revenue, generating only EUR 0.02B in 2025 while burning cash with a net margin of -265%, indicating heavy losses and dependence on funding.
ProQR's platform and pipeline are early-stage and unproven, facing competition from larger gene therapy players like Spark Therapeutics and Editas Medicine, so its edge is weak and easily challenged.
Key events, in time order
None yet
None yet
ProQR Therapeutics is presenting pipeline updates and positive preclinical data for AX-0811, suggesting significant upside potential and broader applications beyond cholestasis.
Main discussion
$PRQR catalyst AX-0810 cohort 3 and follow-up by YE26, AX-0811 healthy- volunteer data by YE26, biliary atresia investigator-initiated trial data in H1 2027, Phase 2 interim analysis by mid-2028.
$PRQR BofA 0811 &pipeline breadth add upside '0811 could build upon recent positive data YE26e, with >4x greater preclinical potency, projected 40% to 65% liver editing, &a more convenient dosing profile with activity lasting over three months. Beyond cholestasis, ProQR is advanc
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
